

The much-anticipated BIOHK2022 finally opened at Hong Kong Convention and Exhibition Centre today.

BIOHK2022 is organized by HKBIO to introduce novel state-of-the-art biotech innovations from around the globe, with the purpose of providing an extensive platform to allow pioneers of the biotech industry to convene.

Mr. Simon Je is the Founder and Chairman of Greater Bay Area International Medical and Healthcare Industry Association (GBA-IMHIA), the Founder & Chairman of Hong Kong International Family Office Association (HKIFOA). GBA-IMHIA and HKIFOA both are supporting organizations of BIOHK2022. These two organizations have been advocating and supporting BIOHK since 2018.

Mr. Je, a committee member of BIOHK2022, attended the Open Ceremony and networked with many Honorary Speakers which included Dr. Su Juan Ba and Dr. Guo-Liang YU this morning.

Dr. Su Juan Ba, President and CEO of the National Foundation for Cancer Research, will be chairing Plenary Session 2 on the topic of "Cancer" in BIOHK 2022 on 15 December at 11:00 am.

Dr. Su Juan Ba led the establishment of NCFR's annual Szent-Györgyi Prize for Progress in Cancer Research, and has served continuously as co-chair of the Prize Selection Committee which consists of leaders in academic and pharmaceutical sectors.

Dr. Su Juan Ba is the Founder and CEO of the Asian Fund for Cancer Research. She co-founded and serves as the Founding CEO of AIM-HI Accelerator Fund, focused on advancing oncology startups through venture philanthropy and impact investments. She was named as one of the "Top 300 Women Leaders in Global Health" in 2015 by the Graduate Institute of International and Development Studies' Global Health Program. She received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.

Prof. Guo-Liang Yu is the Executive Chairman of Crown Bioscience Inc., a publically-listed personalized oncology platform company with ~600 employees globally. He co-founded Epitomics Inc., an antibody biotechnology company,

and served as Chairman, President and CEO for 10 years prior to its acquisition by Abcam for \$170 million.

Prof. Yu's success is driven by his scientific curiosity and passion for translating scientific discovery to real products. After graduating from Fudan University in Shanghai, China, he came to the United States in 1984 to pursue advanced studies. He obtained his Ph.D. from UC Berkeley, where he and Dr. Greider discovered telomerase and its mechanism in Dr. Blackburn's lab. Drs. Blackburn and Greider received Nobel Prize in 2009 for their discovery.

Prof. Yu later joined Dr. Frederick Ausubel's lab at Harvard University to pursue the question of how plants defend themselves against pathogens without an immune system, and was the first person in the world to identify a plant disease resistance gene. In 1993, when genomics was still in its infancy, Prof. Yu joined Human Genome Sciences Inc. as one of the first few senior scientists, identifying human gene targets for drug discovery. Among several important drug targets he studied was BLYS, the first successfully genomic target for the development of a lupus antibody drug Benlysta, which was approved by FDA in 2010.



Simon Je(Left), a committee member of BIOHK2022, interacting with Dr. Su Juan Ba(Center), President and CEO of the National Foundation for Cancer Research, and Prof. Guo-Liang YU(Right), Co-president of BIOHK2022, at the opening ceremony of BIOHK2022.